Related Experiment Video
Updated: Jul 12, 2025
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.3K
MINOCA biomarkers: Non-atherosclerotic aspects
Xiaojian Xu1, Guoliang Zhang1, Zhaoqing Li1
1Department of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao 266100, China.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|October 23, 2023
Summary
Myocardial infarction without obstructive coronary artery disease (MINOCA) poses significant risks despite unclear causes. Identifying biomarkers is crucial for better diagnosis, personalized treatment, and predicting outcomes in MINOCA patients.
Area of Science:
- Cardiology
- Biomarker Discovery
- Pathophysiology
Background:
- Myocardial infarction in the absence of obstructive coronary artery disease (MINOCA) is a significant clinical challenge.
- MINOCA accounts for a substantial proportion of myocardial infarction cases, yet its diagnosis and management remain difficult.
- The underlying pathophysiology of MINOCA is not fully understood, leading to diagnostic and therapeutic uncertainties.
Purpose of the Study:
- To review current diagnostic and therapeutic approaches for MINOCA.
- To highlight the importance of identifying novel biomarkers for MINOCA.
- To discuss the potential of biomarkers in improving diagnosis, treatment individualization, and outcome prediction for MINOCA.
Main Methods:
- Literature review of studies on MINOCA diagnosis and biomarkers.
- Analysis of current understanding of MINOCA pathophysiology.
- Discussion of emerging biomarker research in the context of MINOCA.
Main Results:
- Definitive diagnosis of MINOCA remains challenging despite various recommended approaches.
- A comprehensive understanding of MINOCA pathophysiology is lacking, complicating clinical management.
- Biomarker identification is an active area of research for improving MINOCA care.
Conclusions:
- Improved diagnostic strategies are needed for MINOCA.
- Further research into MINOCA pathophysiology and biomarker discovery is essential.
- Biomarkers hold promise for enhancing the clinical management and prognosis of MINOCA.
Related Concept Videos
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
19
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
19
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
11
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
11
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
99
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
99
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
174
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
174
01:30Coronary Artery Disease I: Introduction
17
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
17
01:26Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11